Switzerland: Oculis going public through SPAC merger

Oculis, a global biopharmaceutical company developing treatments to save sight and improve eye care, is merging with European Biotech Acquisition Corp (EBAC), a listed special purpose acquisition company (SPAC). Upon close of the transaction, expected in H1 2023, the combined company – to be named Oculis Holding – is expected to have a post-transaction enterprise…